Molecules 2014, 19(8), 12349-12367; doi:10.3390/molecules190812349
Review

Berberine, an Epiphany Against Cancer

1,2email, 3email, 1email and 1,* email
Received: 27 June 2014; in revised form: 6 August 2014 / Accepted: 11 August 2014 / Published: 15 August 2014
(This article belongs to the Special Issue Alkaloids: Novel Therapeutic Perspectives)
View Full-Text   |   Download PDF [1094 KB, uploaded 15 August 2014]
Abstract: Alkaloids are used in traditional medicine for the treatment of many diseases. These compounds are synthesized in plants as secondary metabolites and have multiple effects on cellular metabolism. Among plant derivatives with biological properties, the isoquinoline quaternary alkaloid berberine possesses a broad range of therapeutic uses against several diseases. In recent years, berberine has been reported to inhibit cell proliferation and to be cytotoxic towards cancer cells. Based on this evidence, many derivatives have been synthesized to improve berberine efficiency and selectivity; the results so far obtained on human cancer cell lines support the idea that they could be promising agents for cancer treatment. The main properties of berberine and derivatives will be illustrated.
Keywords: apoptosis; autophagy; berberine; cancer; traditional medicine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Guamán Ortiz, L.M.; Lombardi, P.; Tillhon, M.; Scovassi, A.I. Berberine, an Epiphany Against Cancer. Molecules 2014, 19, 12349-12367.

AMA Style

Guamán Ortiz LM, Lombardi P, Tillhon M, Scovassi AI. Berberine, an Epiphany Against Cancer. Molecules. 2014; 19(8):12349-12367.

Chicago/Turabian Style

Guamán Ortiz, Luis M.; Lombardi, Paolo; Tillhon, Micol; Scovassi, Anna I. 2014. "Berberine, an Epiphany Against Cancer." Molecules 19, no. 8: 12349-12367.


Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert